Cancer Drug Resistance
All Journals
Search Log In
Home Articles Special Issues Volumes Webinars Videos
Cancer Drug Resistance
Search Submit
Home Articles Special Issues Volumes Webinars Videos

fig5

From:  Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors
Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors

Figure 5. Changes in total cfRNA vs. outcome in response to various therapies across different tumor types. The bars represent analyses of 154 BC, 84 CRC, 135 NSCLC patient samples. BC: Breast cancer; CRC: colorectal cancer; NSCLC: non-small cell lung cancer.

Cancer Drug Resistance
ISSN 2578-532X (Online)
Navigation
Follow Us
Navigation

Committee on Publication Ethics

https://members.publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Committee on Publication Ethics

https://members.publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/
Discover Content
Follow OAE
Twitter
Facebook
LinkedIn
YouTube
BiLiBiLi
WeChat
© 2016-2025 OAE Publishing Inc., except certain content provided by third parties